CytoSorbents Restores Nasdaq Listing Status
Princeton-based medical device firm CytoSorbents Corporation has officially regained compliance with Nasdaq’s minimum bid price requirement. After maintaining a closing share price of at least $1.00 for ten consecutive trading sessions, the company successfully exited the exchange's watch list, marking a significant milestone in its ongoing financial restructuring efforts.
The Listing Qualifications Department of the Nasdaq Stock Market confirmed the resolution of the matter on September 22, 2026. This development follows a period of volatility that threatened the company's standing on the exchange. CEO Dr. Phillip Chan emphasized that the focus now shifts toward addressing the minimum market value of listed securities requirement, which must be satisfied by December 28, 2026.
Beyond stabilizing its stock market listing, the firm is prioritizing operational efficiency and core business growth. Management aims to reach operating cash flow breakeven in the second half of this year while advancing the DrugSorb-ATR system through the regulatory approval process. These steps are intended to bolster shareholder confidence as the company continues to market its blood purification technologies globally.
Comments (0)
No comments yet. Be the first!